REFERENCES
2. Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 2015;125:3049-58.
3. Bianchi G, Anderson KC. Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back. CA Cancer J Clin 2014;64:422-44.
5. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-48.
6. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol 2018;93:981-1114.
7. Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood 2016;128:2599-606.
8. Guang MHZ, Bianchi G. Targeting protein synthesis and degradation in multiple myeloma: a look at What’s on the Horizon. Am J Hematol Oncol 2017;13:11.
9. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 2002;99:12963-8.
10. Torres EM, Sokolsky T, Tucker CM, Chan LY, Boselli M, et al. Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science 2007;317:916-24.
11. Tsafrir D, Bacolod M, Selvanayagam Z, Tsafrir I, Shia J, et al. Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res 2006;66:2129-37.
12. Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, et al. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol 2006;8:1053-63.
13. Papp I, Markkanen M, von Bonsdorff M. Clinical environment as a learning environment: student nurses’ perceptions concerning clinical learning experiences. Nurse Educ Today 2003;23:262-8.
14. Desantis V, Saltarella I, Lamanuzzi A, Mariggio MA, Racanelli V, et al. Autophagy: a new mechanism of prosurvival and drug resistance in multiple myeloma. Transl Oncol 2018;11:1350-7.
15. Jacob JA, Salmani JMM, Jiang Z, Feng L, Song J, et al. Autophagy: an overview and its roles in cancer and obesity. Clin Chim Acta 2017;468:85-9.
16. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol 2010;221:3-12.
17. Yun Z, Zhichao J, Hao Y, Ou J, Ran Y, et al. Targeting autophagy in multiple myeloma. Leuk Res 2017;59:97-104.
18. Xie Z, Klionsky DJ. Autophagosome formation: core machinery and adaptations. Nat Cell Biol 2007;9:1102-9.
19. Mehrpour M, Esclatine A, Beau I, Codogno P. Autophagy in health and disease. 1. Regulation and significance of autophagy: an overview. Am J Physiol Cell Physiol 2010;298:C776-85.
20. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett 2010;584:1287-95.
21. Nakatogawa H, Suzuki K, Kamada Y, Ohsumi Y. Dynamics and diversity in autophagy mechanisms: lessons from yeast. Nat Rev Mol Cell Biol 2009;10:458.
22. Itakura E, Mizushima N. Characterization of autophagosome formation site by a hierarchical analysis of mammalian Atg proteins. Autophagy 2010;6:764-76.
23. Yang S, Wang X, Contino G, Liesa M, Sahin E, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011;25:717-29.
24. Lee JA, Gao FB. Inhibition of autophagy induction delays neuronal cell loss caused by dysfunctional ESCRT-III in frontotemporal dementia. J Neurosci 2009;29:8506-11.
25. Razi M, Chan EY, Tooze SA. Early endosomes and endosomal coatomer are required for autophagy. J Cell Biol 2009;185:305-21.
26. Park KJ, Lee SH, Kim TI, Lee HW, Lee CH, et al. A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells. Cancer Res 2007;67:7327-34.
27. Chen Y, Sawada O, Kohno H, Le YZ, Subauste C, et al. Autophagy protects the retina from light-induced degeneration. J Biol Chem 2013;288:7506-18.
31. Lemasters JJ. Variants of mitochondrial autophagy: types 1 and 2 mitophagy and micromitophagy (Type 3). Redox Biol 2014;2:749-54.
33. Li WW, Li J, Bao JK. Microautophagy: lesser-known self-eating. Cell Mol Life Sci 2012;69:1125-36.
34. Sahu R, Kaushik S, Clement CC, Cannizzo ES, Scharf B, et al. Microautophagy of cytosolic proteins by late endosomes. Dev Cell 2011;20:131-9.
35. Todde V, Veenhuis M, van der Klei IJ. Autophagy: principles and significance in health and disease. Biochim Biophys Acta 2009;1792:3-13.
36. Kaushik S, Cuervo AM. The coming of age of chaperone-mediated autophagy. Nat Rev Mol Cell Biol 2018;19:365-81.
37. Cuervo AM, Wong E. Chaperone-mediated autophagy: roles in disease and aging. Cell Res 2014;24:92-104.
38. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature 2011;469:323-35.
39. Deretic V, Saitoh T, Akira S. Autophagy in infection, inflammation and immunity. Nat Rev Immunol 2013;13:722-37.
40. Wu TT, Li WM, Yao YM. Interactions between autophagy and inhibitory cytokines. Int J Biol Sci 2016;12:884-97.
41. Djavaheri-Mergny M, Giuriato S, Tschan MP, Humbert M. Therapeutic modulation of autophagy in leukaemia and lymphoma. Cells 2019;8:E103.
42. Mortensen M, Watson AS, Simon AK. Lack of autophagy in the hematopoietic system leads to loss of hematopoietic stem cell function and dysregulated myeloid proliferation. Autophagy 2011;7:1069-70.
43. Warr MR, Binnewies M, Flach J, Reynaud D, Garg T, et al. FOXO3A directs a protective autophagy program in haematopoietic stem cells. Nature 2013;494:323-7.
44. Ho TT, Warr MR, Adelman ER, Lansinger OM, Flach J, et al. Autophagy maintains the metabolism and function of young and old stem cells. Nature 2017;543:205.
45. Ianniciello A, Rattigan KM, Helgason GV. The Ins and Outs of autophagy and metabolism in hematopoietic and leukemic stem cells: food for thought. Front Cell Dev Biol 2018;6:120.
46. Mortensen M, Soilleux EJ, Djordjevic G, Tripp R, Lutteropp M, et al. The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. J Exp Med 2011;208:455-67.
47. Ho Zhi Guang M, Kavanagh EL, Dunne LP, Dowling P, Zhang L, et al. Targeting proteotoxic stress in cancer: a review of the role that protein quality control pathways play in oncogenesis. Cancers 2019;11:66.
48. Nutt SL, Taubenheim N, Hasbold J, Corcoran LM, Hodgkin PD. The genetic network controlling plasma cell differentiation. Semin Immunol 2011;23:341-9.
49. Reimold AM, Iwakoshi NN, Manis J, Vallabhajosyula P, Szomolanyi-Tsuda E, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001;412:300-7.
50. Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 2004;21:81-93.
51. Tellier J, Shi W, Minnich M, Liao Y, Crawford S, et al. Blimp-1 controls plasma cell function through the regulation of immunoglobulin secretion and the unfolded protein response. Nat Immunol 2016;17:323-30.
52. Pengo N, Scolari M, Oliva L, Milan E, Mainoldi F, et al. Plasma cells require autophagy for sustainable immunoglobulin production. Nat Immunol 2013;14:298-305.
53. Halliley JL, Tipton CM, Liesveld J, Rosenberg AF, Darce J, et al. Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow. Immunity 2015;43:132-45.
54. Pengo N, Cenci S. Chapter 6 - autophagy in plasma cells. Autophagy: cancer, other pathologies, inflammation, immunity, infection, and aging Academic Press; 2017. pp. 175-86.
55. Cenci S, Oliva L, Cerruti F, Milan E, Bianchi G, et al. Pivotal advance: protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. J Leukoc Biol 2012;92:921-31.
56. Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013;24:289-304.
57. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007;67:1783-92.
59. Ling SC, Lau EK, Al-Shabeeb A, Nikolic A, Catalano A, et al. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica 2012;97:64-72.
60. Milan E, Fabbri M, Cenci S. Autophagy in plasma cell ontogeny and malignancy. J Clin Immunol 2016;36 Suppl 1:18-24.
61. Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, et al. Aggregated and monomeric alpha-synuclein bind to the S6’ proteasomal protein and inhibit proteasomal function. J Biol Chem 2003;278:11753-9.
62. Yao TP. The role of ubiquitin in autophagy-dependent protein aggregate processing. Genes Cancer 2010;1:779-86.
63. Le T, Bhushan V, Sochat M. . ISBN: 978-1-26-014367-6
64. Milan E, Perini T, Resnati M, Orfanelli U, Oliva L, et al. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells. Autophagy 2015;11:1161-78.
65. Hoang B, Benavides A, Shi Y, Frost P, Lichtenstein A. Effect of autophagy on multiple myeloma cell viability. Mol Cancer Ther 2009;8:1974-84.
66. Caro LH, Plomp PJ, Wolvetang EJ, Kerkhof C, Meijer AJ. 3-Methyladenine, an inhibitor of autophagy, has multiple effects on metabolism. Eur J Biochem 1988;175:325-9.
67. Lamy L, Ngo VN, Emre NC, Shaffer AL 3rd, Yang Y, et al. Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell 2013;23:435-49.
68. Yu L, Alva A, Su H, Dutt P, Freundt E, et al. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science 2004;304:1500-2.
70. Kryston TB, Georgiev AB, Pissis P, Georgakilas AG. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res 2011;711:193-201.
71. Wu W, Tian W, Hu Z, Chen G, Huang L, et al. ULK1 translocates to mitochondria and phosphorylates FUNDC1 to regulate mitophagy. EMBO Rep 2014;15:566-75.
72. Maes H, Rubio N, Garg AD, Agostinis P. Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol Med 2013;19:428-46.
73. Zheng Z, Fan S, Zheng J, Huang W, Gasparetto C, et al. Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma. J Hematol Oncol 2018;11:29.
74. Gourzones-Dmitriev C, Kassambara A, Sahota S, Reme T, Moreaux J, et al. DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment. Cell Cycle 2013;12:2760-73.
75. Cottini F, Hideshima T, Suzuki R, Tai YT, Bianchini G, et al. Synthetic lethal approaches exploiting DNA damage in aggressive myeloma. Cancer Discov 2015;5:972-87.
76. Eliopoulos AG, Havaki S, Gorgoulis VG. DNA damage response and autophagy: a meaningful partnership. Front Genet 2016;7:204.
77. Alexander DE, Gong E, Martin LD, Burnham DA, Falk AR. Model tests of gliding with different hindwing configurations in the four-winged dromaeosaurid microraptor gui. Proc Natl Acad Sci U S A 2010;107:2972-6.
78. Alexander A, Kim J, Walker CL. ATM engages the TSC2/mTORC1 signaling node to regulate autophagy. Autophagy 2010;6:672-3.
79. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 2011;13:132-41.
80. Desantis A, Bruno T, Catena V, De Nicola F, Goeman F, et al. Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy. EMBO J 2015;34:1214-30.
81. Copetti T, Bertoli C, Dalla E, Demarchi F, Schneider C. p65/RelA modulates BECN1 transcription and autophagy. Mol Cell Biol 2009;29:2594-608.
82. Rodriguez-Vargas JM, Ruiz-Magana MJ, Ruiz-Ruiz C, Majuelos-Melguizo J, Peralta-Leal A, et al. ROS-induced DNA damage and PARP-1 are required for optimal induction of starvation-induced autophagy. Cell Res 2012;22:1181-98.
83. Wei Y, Sinha S, Levine B. Dual role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation. Autophagy 2008;4:949-51.
84. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, et al. Regulation of PTEN transcription by p53. Mol Cell 2001;8:317-25.
85. Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, et al. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res 2007;67:3043-53.
86. Buschmann T, Potapova O, Bar-Shira A, Ivanov VN, Fuchs SY, et al. Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol 2001;21:2743-54.
87. Zalckvar E, Berissi H, Eisenstein M, Kimchi A. Phosphorylation of Beclin 1 by DAP-kinase promotes autophagy by weakening its interactions with Bcl-2 and Bcl-XL. Autophagy 2009;5:720-2.
88. Zalckvar E, Berissi H, Mizrachy L, Idelchuk Y, Koren I, et al. DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy. EMBO Rep 2009;10:285-92.
89. Eisenberg-Lerner A, Kimchi A. PKD is a kinase of Vps34 that mediates ROS-induced autophagy downstream of DAPk. Cell Death Differ 2012;19:788-97.
90. Crighton D, Wilkinson S, O’Prey J, Syed N, Smith P, et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006;126:121-34.
91. Kim JS, Ro SH, Kim M, Park HW, Semple IA, et al. Sestrin2 inhibits mTORC1 through modulation of GATOR complexes. Sci Rep 2015;5:9502.
92. Park BC, Kim TH, Sim KI, Kang B, Kim JW, et al. Terahertz single conductance quantum and topological phase transitions in topological insulator Bi(2)Se(3) ultrathin films. Nat Commun 2015;6:6552.
93. Liu IB, Gharbi MA, Ngo VL, Kamien RD, Yang S, et al. Elastocapillary interactions on nematic films. Proc Natl Acad Sci U S A 2015;112:6336-40.
94. Hewitt G, Carroll B, Sarallah R, Correia-Melo C, Ogrodnik M, et al. SQSTM1/p62 mediates crosstalk between autophagy and the UPS in DNA repair. Autophagy 2016;12:1917-30.
95. Qiang L, Zhao B, Shah P, Sample A, Yang S, et al. Autophagy positively regulates DNA damage recognition by nucleotide excision repair. Autophagy 2016;12:357-68.
96. Wang Z, Miao G, Xue X, Guo X, Yuan C, et al. The Vici syndrome protein EPG5 is a Rab7 effector that determines the fusion specificity of autophagosomes with late endosomes/lysosomes. Mol Cell 2016;63:781-95.
97. Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, et al. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev 2007;21:1367-81.
98. Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G, Mathew R, et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev 2007;21:1621-35.
99. Harada T, Hideshima T, Anderson KC. Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. Int J Hematol 2016;104:300-9.
100. Kaliszczak M, van Hechanova E, Li Y, Alsadah H, Parzych K, et al. The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death. Br J Cancer 2018;119:1278-87.
101. Iwata A, Riley BE, Johnston JA, Kopito RR. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 2005;280:40282-92.
102. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003;115:727-38.
103. Ouyang H, Ali YO, Ravichandran M, Dong A, Qiu W, et al. Protein aggregates are recruited to aggresome by histone deacetylase 6 via unanchored ubiquitin C termini. J Biol Chem 2012;287:2317-27.
104. Banreti A, Sass M, Graba Y. The emerging role of acetylation in the regulation of autophagy. Autophagy 2013;9:819-29.
105. Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J 2010;29:969-80.
106. Hideshima T, Qi J, Paranal RM, Tang W, Greenberg E, et al. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A 2016;113:13162-7.
107. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005;102:8567-72.
108. Santo L, Cirstea DD, Eda H, Nemani N, Arastu-Kapur S, et al. Inhibition of autophagy by ACY-1215, a selective HDAC6 inhibitor accelerates carfilzomib-induced cell death in multiple myeloma. Blood 2013;122:4431.
109. Huang FI, Wu YW, Sung TY, Liou JP, Lin MH, et al. MPT0G413, a novel HDAC6-selective inhibitor, and Bortezomib synergistically exert anti-tumor activity in multiple myeloma cells. Front Oncol 2019;9:249.
110. Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19:344-56.
111. Pan Y, Gao Y, Chen L, Gao G, Dong H, et al. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy. Clin Cancer Res 2011;17:3248-58.
112. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol 2010;190:881-92.
113. Guo X, He D, Zhang E, Chen J, Chen Q, et al. HMGB1 knockdown increases MM cell vulnerability by regulating autophagy and DNA damage repair. J Exp Clin Cancer Res 2018;37:205.
114. Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, et al. Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nature Communications 2019;10:1486.
115. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013;31:51-72.
116. Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ 2013;21:69.
117. Joubert PE, Albert ML. Antigen cross-priming of cell-associated proteins is enhanced by macroautophagy within the antigen donor cell. Front Immunol 2012;3:61.
118. Niewerth D, Jansen G, Assaraf YG, Zweegman S, Kaspers GJ, et al. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updat 2015;18:18-35.
119. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008;14:1649-57.
120. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008;11:164-79.
121. Yong K, Gonzalez-McQuire S, Szabo Z, Schoen P, Hajek R. The start of a new wave: developments in proteasome inhibition in multiple myeloma. Eur J Haematol 2018; doi: 10.1111/ejh.13071.
122. Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2009;113:3040-9.
123. Kawaguchi T, Miyazawa K, Moriya S, Ohtomo T, Che XF, et al. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress. Int J Oncol 2011;38:643-54.
124. Qiao L, Zhang J. Inhibition of lysosomal functions reduces proteasomal activity. Neurosci Lett 2009;456:15-9.
125. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007;447:859-63.
126. Wu WK, Cho CH, Lee CW, Wu YC, Yu L, et al. Macroautophagy and ERK phosphorylation counteract the antiproliferative effect of proteasome inhibitor in gastric cancer cells. Autophagy 2010;6:228-38.
127. Kouroku Y, Fujita E, Tanida I, Ueno T, Isoai A, et al. ER stress (PERK/eIF2alpha phosphorylation) mediates the polyglutamine-induced LC3 conversion, an essential step for autophagy formation. Cell Death Differ 2007;14:230-9.
128. Ding WX, Ni HM, Gao W, Yoshimori T, Stolz DB, et al. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 2007;171:513-24.
129. Lu Y, Wang Y, Xu H, Shi C, Jin F, et al. Profilin 1 induces drug resistance through Beclin1 complex-mediated autophagy in multiple myeloma. Cancer Sci 2018;109:2706-16.
130. Wang G, Zhou P, Chen X, Zhao L, Tan J, et al. The novel autophagy inhibitor elaiophylin exerts antitumor activity against multiple myeloma with mutant TP53 in part through endoplasmic reticulum stress-induced apoptosis. Cancer Biol Ther 2017;18:584-95.
131. Jagannathan S, Abdel-Malek MA, Malek E, Vad N, Latif T, et al. Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib. Leukemia 2015;29:2184-91.
132. Wang Y, Xu W, Yan Z, Zhao W, Mi J, et al. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways. J Exp Clin Cancer Res 2018;37:63.
133. Granato M, Gilardini Montani MS, Romeo MA, Santarelli R, Gonnella R, et al. Metformin triggers apoptosis in PEL cells and alters bortezomib-induced unfolded protein response increasing its cytotoxicity and inhibiting KSHV lytic cycle activation. Cell Signal 2017;40:239-47.
134. Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, et al. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 2008;111:4690-9.
135. Zhou H, Luo W, Zeng C, Zhang Y, Wang L, et al. PP2A mediates apoptosis or autophagic cell death in multiple myeloma cell lines. Oncotarget 2017;8:80770-89.
136. Chen S, Zhang Y, Zhou L, Leng Y, Lin H, et al. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood 2014;124:2687-97.
137. Baranowska K, Misund K, Starheim KK, Holien T, Johansson I, et al. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells. Oncotarget 2016;7:70845-56.
138. Ismail SI, Mahmoud IS, Msallam MM, Sughayer MA. Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma. Leuk Res 2010;34:824-6.
139. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585.
140. Ramakrishnan V, Kumar S. PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise. Leuk Lymphoma 2018;59:2524-34.
141. Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004;104:4188-93.
142. Yan H, Frost P, Shi Y, Hoang B, Sharma S, et al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res 2006;66:2305-13.
143. Ramakrishnan V, Kimlinger T, Timm M, Haug J, Rajkumar SV, et al. Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001. Leuk Res 2014;38:1358-66.
144. Simmons JK, Patel J, Michalowski A, Zhang S, Wei BR, et al. TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms. Mol Oncol 2014;8:261-72.
145. Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, et al. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2010;29:1190-202.
146. Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, et al. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res 2006;12:6826-35.
147. Baumann P, Hagemeier H, Mandl-Weber S, Franke D, Schmidmaier R. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001. Anticancer Drugs 2009;20:259-66.
148. Ramakrishnan V, Kimlinger T, Haug J, Painuly U, Wellik L, et al. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. PLoS One 2012;7:e50005.
149. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006;107:4053-62.
150. Mimura N, Hideshima T, Shimomura T, Suzuki R, Ohguchi H, et al. Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. Cancer Res 2014;74:4458-69.
151. McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, et al. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 2009;69:5835-42.
152. Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res 2009;315:485-97.
153. Aronson LI, Davenport EL, Mirabella F, Morgan GJ, Davies FE. Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application. Leukemia 2013;27:2397.
154. Li Z, Srivastava P. Heat-shock proteins. Curr Protoc Immunol 2004; . Appendix 1:Appendix 1T
155. Agarraberes FA, Terlecky SR, Dice JF. An intralysosomal hsp70 is required for a selective pathway of lysosomal protein degradation. J Cell Biol 1997;137:825-34.
156. Chiang HL, Terlecky SR, Plant CP, Dice JF. A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. Science 1989;246:382-5.
157. Wang B, Chen Z, Yu F, Chen Q, Tian Y, et al. Hsp90 regulates autophagy and plays a role in cancer therapy. Tumour Biol 2016;37:1-6.
158. Zhang L, Fok JH, Davies FE. Heat shock proteins in multiple myeloma. Oncotarget 2014;5:1132-48.
159. Marcu MG, Doyle M, Bertolotti A, Ron D, Hendershot L, et al. Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha. Mol Cell Biol 2002;22:8506-13.
160. Chatterjee M, Andrulis M, Stuhmer T, Muller E, Hofmann C, et al. The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica 2013;98:1132-41.
161. Braunstein MJ, Scott SS, Scott CM, Behrman S, Walter P, et al. Antimyeloma effects of the heat shock protein 70 molecular chaperone inhibitor MAL3-101. J Oncol 2011;2011:232037.
162. Ishii T, Seike T, Nakashima T, Juliger S, Maharaj L, et al. Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J 2012;2:e68.
163. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A 2006;103:17408-13.
164. Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004;3:551-66.
165. Lamottke B, Kaiser M, Mieth M, Heider U, Gao Z, et al. The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. Eur J Haematol 2012;88:406-15.
166. Stuhmer T, Iskandarov K, Gao Z, Bumm T, Grella E, et al. Preclinical activity of the novel orally bioavailable HSP90 inhibitor NVP-HSP990 against multiple myeloma cells. Anticancer Res 2012;32:453-62.
167. Beebe K, Mollapour M, Scroggins B, Prodromou C, Xu W, et al. Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors. Oncotarget 2013;4:1065-74.
168. Usmani SZ, Bona RD, Chiosis G, Li Z. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. J Hematol Oncol 2010;3:40.
169. Stuhmer T, Zollinger A, Siegmund D, Chatterjee M, Grella E, et al. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 2008;22:1604-12.
170. Bailey CK, Budina-Kolomets A, Murphy ME, Nefedova Y. Efficacy of the HSP70 inhibitor PET-16 in multiple myeloma. Cancer Biol Ther 2015;16:1422-6.
171. Zhang L, Fok JJ, Mirabella F, Aronson LI, Fryer RA, et al. Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress. Cancer Lett 2013;339:49-59.
172. Davenport EL, Zeisig A, Aronson LI, Moore HE, Hockley S, et al. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia 2010;24:1804-7.
173. Yasui H, Hideshima T, Ikeda H, Jin J, Ocio EM, et al. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. Br J Haematol 2007;136:414-23.
174. Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008;14:250-62.
175. Fok JHL, Hedayat S, Zhang L, Aronson LI, Mirabella F, et al. HSF1 is essential for myeloma cell survival and a promising therapeutic target. Clin Cancer Res 2018;24:2395-407.
176. Onorati AV, Dyczynski M, Ojha R, Amaravadi RK. Targeting autophagy in cancer. Cancer 2018;124:3307-18.
177. Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 2014;10:1380-90.
178. Montanari F, Lu M, Marcus S, Saran A, Malankar A, et al. A phase II trial of chloroquine in combination with bortezomib and cyclophosphamide in patients with relapsed and refractory multiple myeloma. Blood 2014;124:5775.
179. Scott EC, Maziarz RT, Spurgeon SE, Medvedova E, Gajewski J, et al. Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma. Haematologica 2017;102:e261-5.
180. Xie X, White EP, Mehnert JM. Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS One 2013;8:e55096.
181. Harada T, Hideshima T, Anderson KC. Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. Int J Hematol 2016;104:300-9.
182. Yee AJ, Bensinger WI, Supko JG, Voorhees PM, Berdeja JG, et al. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Lancet Oncol 2016;17:1569-78.
183. Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, et al. Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with Bortezomib and Dexamethasone for relapsed or refractory multiple myeloma. Clin Cancer Res 2017;23:3307-15.
184. Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, et al. Tanespimycin with Bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol 2010;150:428-37.
185. Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, et al. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin Cancer Res 2010;16:2792-802.
186. Yong K, Cavet J, Johnson P, Morgan G, Williams C, et al. Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies. Br J Cancer 2016;114:7-13.
187. Cavenagh J, Oakervee H, Baetiong-Caguioa P, Davies F, Gharibo M, et al. A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Br J Cancer 2017;117:1295-302.
188. Günther A, Baumann P, Burger R, Kellner C, Klapper W, et al. Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. Haematologica 2015;100:541-7.
189. Yee AJ, Hari P, Marcheselli R, Mahindra AK, Cirstea DD, et al. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol 2014;166:401-9.
190. Hitz F, Pabst T, Hess D, Kraus M, Besse L, et al. Nelfinavir and Lenalidomide/Dexamethasone in patients with lenalidomide-refractory multiple myeloma. A Phase I/II Trial - SAKK 39/10. Blood 2017;130:1884.
